Giuseppe Tarantini
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Introduction Pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) are key haemodynamic indicators of cardiac congestion. Atrial fibrillation (AF) often coexists with several heart diseases, making it challenging to determine AF’s independent contribution to atrial pressure elevation. Therefore, the impact of AF on PCWP and RAP requires clarification. We sought to quantify the contribution of AF on PCWP and RAP within patients with various chronic heart diseases. Methods We performed a single-center retrospective analysis on 1452 patients (age: 68.0 ± 13.6 years, 58.7% male, 26% AF) with chronic heart diseases undergoing right heart catheterization (RHC). PCWP and RAP were measured during RHC, and the underlying AF or sinus rhythm (SR) was annotated. To isolate AF effect from clinical, haemodynamic, and echocardiographic confounders, two propensity score matching analyses yielded two balanced cohorts for PCWP (n = 496) and RAP (n = 494) analysis. Results After matching, PCWP was higher in the AF than the SR group (18.4 ± 0.49 mmHg vs 15.7 ± 0.49 mmHg; P < .001). Similarly, RAP was higher in the AF than the SR group (8.7 ± 0.34 mmHg vs 7.5 ± 0.34 mmHg; P = .02). The findings were highly robust for PCWP (E-value = 10.8) and moderately robust for RAP (E-value = 2.78) to unmeasured confounders. Additionally, patients in the SR cohort with a prior history of AF had significantly higher PCWP and RAP compared to patients with no AF history. Conclusion In our cohort, AF increased PCWP by 2.6 mmHg and RAP by 1.1 mmHg. Furthermore, a previous history of AF is linked to higher atrial pressures in patients later in SR.
Year:
2026
Aims Transvenous lead extraction (TLE) is potentially complicated by significant tricuspid valve regurgitation increase (TRI). However, there are limited data on the effect of the bidirectional rotational mechanical sheaths on significant TRI. The aim of the present study was to investigate the rate of significant changes in tricuspid regurgitation (TR) severity following mechanical rotational TLE and their outcomes. Methods and results In 158 patients (mean age 66 ± 16.9 years) undergoing mechanical rotational TLE, acute changes in TR severity were assessed by echocardiography evaluation. A significant acute TRI was defined as an increase of at least one grade with a post-extraction severity at least moderate. A total of 290 leads were extracted (mean implant duration, 93 ± 65 months). Significant TRI was noted in 5.7% of patients, and it was linked to tricuspid valve damage, TLE infection indication, and longer lead implant duration. Univariate predictors of significant TRI included implant duration of all leads [odds ratio (OR) 1.01; 95% confidence interval (CI) 1.003–1.018; P = 0.001] and right ventricular leads (OR 1.01; 95% CI 1.004–1.017; P = 0.002). Severe increase of TR following TLE was an independent predictor of mortality [hazard ratio (HR) 5.20; 95% CI 1.44–18.73; P = 0.012 ] along with severe systolic dysfunction (HR 2.37; 95% CI 1.01–5.20; P = 0.032), and systemic infection (HR 2.28; 95% CI 1.06–4.89; P = 0.035). Conclusion Significant TRI was detected in 5.7% of patients following transvenous rotational mechanical lead extraction. The duration of lead implantation emerged as the sole predictor of significant TRI. Physicians engaged in TLE should exercise greater vigilance for this potential complication.
Year:
2024
Background Minimally invasive mitral valve repair has a favorable risk–benefit profile in patients with significant de novo mitral regurgitation. Its role in patients with prior mitral valve repair is uncertain. We aimed to appraise the outcome of patients undergoing transcatheter edge‐to‐edge repair (TEER) with prior transcatheter or surgical mitral valve repair (SMVR). Methods and Results We queried the Italian multicenter registry on TEER with MitraClip, distinguishing naïve patients from those with prior TEER or (SMVR). Inhospital and long‐term clinical/echocardiographic outcomes were appraised. The primary outcome was the occurrence of death or rehospitalization for heart failure. A total of 2238 patients were included, with 2169 (96.9%) who were naïve to any mitral intervention, 29 (1.3%) with prior TEER, and 40 (1.8%) with prior SMVR. Several significant differences were found in baseline clinical and imaging features. Respectively, device success was obtained in 2120 (97.7%), 28 (96.6%), and 38 (95.0%, P =0.261) patients; procedural success in 2080 (95.9%), 25 (86.2%), and 38 (95.0%; P =0.047); and inhospital death in 61 (2.8%), 1 (3.5%), and no ( P =0.558) patients. Clinical follow‐up after a mean of 14 months showed similar rates of death, cardiac death, rehospitalization, rehospitalization for heart failure, and their composite (all P >0.05). Propensity score–adjusted analysis confirmed unadjusted analysis, with lower procedural success for the prior TEER group (odds ratio, 0.28 [95% CI, 0.09–0.81]; P =0.019) but similar odds ratios and hazard ratios for all other outcomes in the naïve, TEER, and SMVR groups (all P >0.05). Conclusions In carefully selected patients, TEER can be performed using the MitraClip device even after prior TEER or SMVR.
Year:
2024
Coronary artery disease (CAD) is a frequent finding in patients with aortic stenosis (AS). Concomitant coronary artery bypass and aortic valve replacement is considered the gold standard treatment in surgical candidates. However, limited evidence is available regarding the role of coronary revascularization in patients undergoing transcatheter aortic valve implantation (TAVI). How to evaluate CAD severity in patients with AS, whether percutaneous coronary intervention (PCI) needs to be performed and what is the timing for revascularization to minimize procedural risks, remains matters of debate. The aim of this review is to summarize epidemiology, diagnostic tools and possible options for CAD management in patients undergoing TAVI with specific focus on the pros and the cons of the different timing of PCI.
Year:
2023
Collaborators (11)
Domenico Corrado
Full professor of cardiology
University of Padova
Federico Migliore
Associate Professor
University of Padua
Valeria Pergola
University of Padua
Emmanuel Villa
Fondazione Poliambulanza Istituto Ospedaliero
Angelo Squeri
Head of Integrated Cardiovascular imaging dpt
-
Gino Gerosa
Full professor of Cardiac Surgery
University of Padova
Gaetano Thiene
Professor
-
Paolo Denti
Responsible for Percutaneous Structural Heart Treatment
Ospedale San Raffaele
Martina Perazzolo Marra
-
Giuseppe Biondi-Zoccai
Associate Professor
Sapienza University of Rome
Marianna Adamo
University of Brescia
Make your next move.
Prepare your application
Review drafts before you send them.